Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor Combined With Azacytidine and HAG for R/R AML
NCT04722952Phase 3Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2021
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Remission, Incomplete Blood Count Recovery, Partial Remission at 8 months. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04722952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722952.